TY  -  
T1  - Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin 
SN  -  /  
UR  - http://hdl.handle.net/10138/277463 
T3  -  
A1  - Narvi, Elli; Vaparanta, Katri; Karrila, Anna; Chakroborty, Deepankar; Knuutila, Sakari; Pulliainen, Arto; Sundvall, Maria; Elenius, Klaus 
A2  -  
PB  -  
Y1  - 2018 
LA  - eng 
AB  - Therapeutic protocols including EGFR antibodies in the context of oxaliplatin-based regimens have variable clinical effect in colorectal cancer. Here, we tested the effect of the EGFR antibody cetuximab in different sequential combinations with oxaliplatin on the growth of colorectal cancer cells in vitro and in vivo. Cetuximab reduced the efficacy of oxaliplatin when administered before oxaliplatin but provided additive effect when administered after oxaliplatin regardless of the KRAS or BRAF m... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - ANTICANCER DRUGS; INHIBITORS; STAT3; CHEMOTHERAPY; COMBINATION; GEFITINIB; THERAPY; ACTIVATION; RESISTANCE; APOPTOSIS; 3111 Biomedicine; 3122 Cancers 
N1  -   
PP  -  
ER  -